FDA Approves Topical Cream for Inflammatory Rosacea

The FDA approved benzoyl peroxide 5% cream (Epsolay) for adults with inflammatory lesions of rosacea. The medication uses silica-based microcapsules that create a barrier between the skin and active ingredient, and is designed to slowly release benzoyl peroxide over time to provide a favorable efficacy and safety profile.

The FDA approved benzoyl peroxide 5% cream based on data from two 12-week phase 3 trials with 733 adult participants with rosacea randomized to either benzoyl peroxide or a vehicle solution. Benzoyl peroxide–treated patients had a 70% reduction in inflammatory lesions from baseline after 12 weeks of treatment versus 38% to 46% for those who received vehicle without active ingredient.

Benzoyl peroxide 5% cream can cause photosensitivity, so patients should be advised to avoid sun while using this medication. Consult product labeling for important safety and prescribing information.

Benzoyl peroxide 5% cream is a product of Sol-Gel Technologies and will be marketed by Galderma.

Join our email list

Get new course alerts, newsletters and more delivered directly to your inbox

By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.